Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Real-world Evidence With Long-Acting User-optimized Growth Hormone Therapy in Pediatric Growth Hormone Deficiency (REAL-LAUGH)

10 novembre 2026 aggiornato da: Fundació Sant Joan de Déu

The REAL-LAUGH study will compare changes in body composition and other health outcomes in children and adolescents with growth hormone deficiency who start weekly or daily growth hormone treatment in routine clinical practice in Spain.

Approximately 110 participants aged 3 to 16 years will be enrolled: 55 receiving weekly long-acting growth hormone and 55 receiving daily recombinant human growth hormone. The treating physician will select treatment as part of usual care, independently of study participation. The study will not assign treatment.

Participants will be followed for 12 months, with assessments at baseline, 6 months, and 12 months. The main outcome is the change in percentage total body fat measured by dual-energy X-ray absorptiometry, also called DXA, between baseline and 12 months. The study will assess whether the reduction in body fat with weekly treatment differs from that with daily treatment.

Other assessments will include lean body mass, growth, waist measurements, blood pressure, glucose and lipid metabolism, carotid artery wall thickness, bone mineral density, pubertal development, bone age, IGF-1 concentrations, and adverse events. No biological samples will be stored for research.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

110

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Marta Ramon Krauel, MD PhD
  • Numero di telefono: 71702 +34 932 804 000
  • Email: marta.ramon@sjd.es

Luoghi di studio

      • Santiago de Compostela, Spagna
        • Hospital Clínico Universitario de Santiago
        • Contatto:
    • Barcelona
      • Barcelona, Barcelona, Spagna, 08950
        • Hospital Sant Joan de Déu
        • Contatto:
          • Marta Ramon Krauel, MD PhD
          • Numero di telefono: 71702 +34 932 804 000
          • Email: marta.ramon@sjd.es
    • Madrid
    • Valencia
      • Valencia, Valencia, Spagna
    • Zaragoza
      • Zaragoza, Zaragoza, Spagna
        • Hospital Universitario Miguel Servet
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 3 anni a 16 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Children and adolescents aged 3 to 16 years with growth hormone deficiency who attend participating pediatric endocrinology departments in Spain and are initiating either weekly long-acting growth hormone or daily recombinant human growth hormone in routine clinical practice. Eligible candidates will be identified during routine clinical visits and invited to participate.

Descrizione

Inclusion Criteria:

  • Age between 3 and 16 years.
  • Diagnosis of growth hormone deficiency according to standard clinical practice in Spain and the applicable Spanish Ministry of Health criteria.
  • Growth hormone treatment approved by the relevant local authorities and institution.
  • Initiation of treatment with long-acting growth hormone or daily recombinant human growth hormone.

Exclusion Criteria:

- Recombinant human growth hormone prescribed for an indication other than growth hormone deficiency.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Weekly Long-Acting Growth Hormone

Children and adolescents with growth hormone deficiency initiating once-weekly somatrogon as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

LAGH administered by subcutaneous injection once weekly as part of routine clinical care. Prescribed doses and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Altri nomi:
  • Somatrogone
  • NGENLA
Daily Recombinant Human Growth Hormone

Children and adolescents with growth hormone deficiency initiating daily somatropin as prescribed in routine clinical practice. Treatment selection, initiation, dosing, and subsequent modifications are determined by the treating physician independently of study participation.

Human recombinant growth hormone administered by daily subcutaneous injection as part of routine clinical care. Prescribed products, doses, and dose adjustments will be determined by the treating physician and recorded by the study. Treatment is not assigned by the protocol.

Altri nomi:
  • Somatropina
  • Norditropina
  • Omnitropo
  • Genotonorma

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Percentage Total Body Fat
Lasso di tempo: Baseline and 12 months

Change in percentage total body fat measured by dual-energy X-ray absorptiometry (DXA), calculated as the 12-month value minus the baseline value and expressed in percentage points. Percentage total body fat is calculated as total fat mass divided by total body mass, multiplied by 100. Negative changes indicate a reduction in percentage total body fat. The adjusted between-cohort difference in change, defined as long-acting growth hormone minus daily recombinant human growth hormone, will be evaluated.

Baseline and 12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Lean Body Mass
Lasso di tempo: Baseline and 12 months

Change in lean body mass measured by DXA, calculated as the 12-month value minus the baseline value and expressed in kilograms.

Baseline and 12 months
Change in body mass index standard deviation score (BMI-SDS)
Lasso di tempo: Baseline and 12 months

Change in age- and sex-standardized BMI-SDS from baseline to 12 months. Weight and height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in height standard deviation score (SDS)
Lasso di tempo: Baseline and 12 months

Change in height SDS from baseline to 12 months. Height will be used to calculate BMI-SDS based on World Health Organization tables.

Baseline and 12 months
Change in Waist Circumference
Lasso di tempo: Baseline and 12 months

Change in waist circumference from baseline to 12 months, expressed in centimeters.

Baseline and 12 months
Change in Waist-to-Hip Ratio
Lasso di tempo: Baseline and 12 months

Change in waist circumference divided by hip circumference from baseline to 12 months. The ratio is dimensionless.

Baseline and 12 months
Change in Systolic Blood Pressure
Lasso di tempo: Baseline and 12 months

Change in systolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Diastolic Blood Pressure
Lasso di tempo: Baseline and 12 months

Change in diastolic blood pressure from baseline to 12 months, expressed in mmHg.

Baseline and 12 months
Change in Fasting Glucose Concentration
Lasso di tempo: Baseline and 12 months

Change in fasting blood glucose concentration from baseline to 12 months.

Baseline and 12 months
Change in Fasting Insulin Concentration
Lasso di tempo: Baseline and 12 months

Change in fasting blood insulin concentration from baseline to 12 months.

Baseline and 12 months
Change in HOMA-IR
Lasso di tempo: Baseline and 12 months

Change in the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin concentrations, from baseline to 12 months.

Baseline and 12 months
Change in Total Cholesterol Concentration
Lasso di tempo: Baseline and 12 months

Change in total cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in LDL Cholesterol Concentration
Lasso di tempo: Baseline and 12 months

Change in LDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in HDL Cholesterol Concentration
Lasso di tempo: Baseline and 12 months

Change in HDL cholesterol concentration from baseline to 12 months.

Baseline and 12 months
Change in Triglyceride Concentration
Lasso di tempo: Baseline and 12 months

Change in Triglyceride concentration from baseline to 12 months.

Baseline and 12 months
Change in Change in Carotid Intima-Media Thickness
Lasso di tempo: Baseline and 12 months

Change in carotid intima-media thickness measured bilaterally by high-resolution ultrasound at baseline and 12 months, expressed in millimeters.

Baseline and 12 months
Change in Bone Mineral Density Z-Score
Lasso di tempo: Baseline and 12 months

Change in bone mineral density Z-score measured by DXA from baseline to 12 months.

Baseline and 12 months
Change in Height Standard Deviation Score
Lasso di tempo: Baseline and 12 months

Change in height standard deviation score (height SDS) from baseline to 12 months.

Baseline and 12 months
Change in Growth Velocity Standard Deviation Score
Lasso di tempo: Baseline and 12 months

Change in growth velocity standard deviation score from baseline to 12 months.

Baseline and 12 months
Change in Bone Age Minus Chronological Age
Lasso di tempo: Baseline and 12 months

Change in the difference between bone age and chronological age from baseline to 12 months, expressed in years. Bone age will be assessed by manual reading using the Greulich and Pyle atlas.

Baseline and 12 months
Change in IGF-1 standard deviation score
Lasso di tempo: Baseline and 12 months

Change in insulin-like growth factor 1 (IGF-1) standard deviation score from baseline to 12 months.

Baseline and 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • EOM-17-26

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data sharing with external researchers is not planned under the current protocol. Any future third-party data communication would require prior institutional assessment and authorization. The protocol limits such communication to aggregated data from which participants cannot reasonably be identified.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .